Kornimate/medical-research-clean huggingface dataset:
fungal infections during and after the sars-cov-2 pandemic: a retrospective comparison

Conditions: Fungal Infections

Summary: his study aims to retrospectively compare fungal positivity rates between the sars-cov-2 pandemic and the post-pandemic periods. during the pandemic, candida species had a positivity rate of 17.36%, and aspergillus had a rate of 2.22%. post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. the overall fungal positivity rate decreased from 9.15% during the pandemic to 5.13% post-pandemic. statistical analysis revealed a significant decrease in fungal positivity rates post-pandemic (p \< 0.01). these findings underscore the effectiveness of post-pandemic healthcare interventions and infection control strategies.

the study aims to retrospectively compare fungal positivity rates by focusing on candida and aspergillus species during the sars-cov-2 pandemic and in the post-pandemic period. the dataset includes samples collected during the pandemic period (n=623) and the subsequent post-pandemic period (n=818). fungal positivity rates were calculated and statistically analyzed using chi-square tests, and significance was determined as p\<0.01. during the sars-cov-2 pandemic, candida species showed a positivity rate of 17.36%, while the rate in the post-pandemic period significantly decreased to 9.29% (p=0.002). in contrast, aspergillus species did not show a significant change in positivity rates between the pandemic (2.22%) and post-pandemic (1.00%) periods (p=0.186, ns). overall, the study provides valuable insights into the epidemiology of fungal infections during and after the sars-cov-2 pandemic, suggesting possible shifts in fungal pathogen prevalence and healthcare priorities. the findings contribute to the development of targeted healthcare strategies and surveillance measures for fungal infections in the post-pandemic era. study design: retrospective comparative analysis data analysis: chi-square tests, p\<0.01 considered significant

Eligibility criteria:
inclusion criteria: patients over 18 years of age of both genders exclusion criteria: * patients under 18 years of age, * patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization

Keywords: fungal infections, sars-cov-2, pandemic, post-pandemic
maintenance and cost effectiveness of cendres metaux locator (cm-loc) resin matrix versus ball nylon matrix attachment retaining single implant mandibular complete overdentures

Conditions: Completely Edentulous

Summary: the single implant overdenture (iod) represent the simplest form of iods compared to the 2 iod which is the traditional gold standard iod treatment option. mandibular single-implant overdentures are proven to be a successful treatment option for older edentulous adults but we need to know if the cm-loc attachment will retain its superiority over the ball attachments intraorally regarding the prosthetic complications in single implant retained overdenture like in 2 iod


Eligibility criteria:
inclusion criteria: * completely edentulous male or female patients between the ages of 50 to 69. * no contraindications for implantation. * each patient has to perform both a random blood sugar and glycosylated hemoglobin analysis. patients with a glycosylated hemoglobin test hba1c up to 8% and a normal blood sugar level (79 to 110) or controlled diabetic patients (90-130 fasting according to american association of diabetes) will be included. * sufficient bone width (≥ 6 mm) in the anterior region to place an implant. it could be either normally present or achieved by bone plateauing. this will be confirmed by cone beam computed tomographic (cbct) scans. * residual bone height ranging from 11-20 mm with the lowest vertical height in the midline of the mandible not less than 13 mm (class ii or iii according to mcgarry et al\[1\] 1999). this will be confirmed by the cbct. * patients seeking to install a single symphyseal implant and for whom new dentures will be constructed. * patients, who are dissatisfied with the retention and stability of their technically satisfactory dentures. * patients, who already have existing maxillary and mandibular complete dentures, and after examination of the mandibular dentures, it is found that there are technical problems with regard to denture design and/or occlusion; then new maxillary and mandibular dentures will be fabricated * all patients should have adapted to their dentures for at least six weeks before being included in the trial. * patients providing written informed consents to participate in the trial and this will be done before the scheduled date for implant installation. exclusion criteria: * patients with a systemic or local contra-indication for implant placement. * satisfied patients with the retention of their mandibular denture as well as unsatisfied patients with their maxillary denture. * patient with a mandibular denture height less than 6 mm between the base of the denture and the incisal edge of the central incisors (as measured by a caliper) or with 12 mm crown height space as measured by a ruler from the incisal edge till the crest of the ridge. this will be done from a putty index of the diagnostic set up. * incompliant and not cooperative patients. * patients smoking more than 10 cigarettes per day

Keywords: single implant retained mandibular overdenture
tesetaxel as second-line therapy for patients with advanced melanoma and normal serum ldh

Conditions: Melanoma

Summary: tesetaxel is an orally administered chemotherapy agent of the taxane class. this study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (ldh).


Eligibility criteria:
primary inclusion criteria: * histologically confirmed diagnosis of melanoma * progressive disease that is not surgically resectable, or metastatic stage iv disease * measurable disease (revised recist; version 1.1) * serum ldh not more than 1.1 times the upper limit of normal * eastern cooperative oncology group performance status 0 or 1 * treatment with 1 prior regimen (including cytotoxic chemotherapy, immunotherapy, radiation therapy, or cytokine, biologic, or vaccine therapy) as first-line treatment for metastatic disease (administration of interleukin-2 or interferon as adjuvant therapy is allowed and is not to be considered in determining the 1 prior treatment regimen administered as first-line treatment for metastatic disease.) * adequate bone marrow, hepatic, and renal function, as specified in the protocol * at least 3 weeks and recovery from effects of prior surgery or other therapy with an approved or investigational agent * ability to swallow an oral solid-dosage form of medication primary exclusion criteria: * history or presence of brain metastasis or leptomeningeal disease * primary ocular or mucosal melanoma * significant medical disease other than cancer * organ allograft * presence of neuropathy \> grade 1 (national cancer institute common toxicity criteria \[nci ctc\]; version 4.0) * prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other than a vinca alkaloid * need to continue any regularly-taken medication that is a potent inhibitor or inducer of the cyp3a pathway or p-glycoprotein activity
effect of moringa leaf extract on disease activity in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: intervention therapy study of moringa oliefera extract on the degree of activity of rheumatoid arthritis patients. the research subjects were patients with rheumatoid arthritis-intervention with moringa oliefera for 30 days.

rheumatoid arthritis is a progressive autoimmune disease. delay in therapy and delay in remission will result in disability. this study is a randomized clinical trial using a new drug for rheumatoid arthritis, moringa oliefera. the choice of moringa oliefera was due to the ability of moringa oliefera in anti-inflammatory and immunosuppressant terms. this drug has also been proven in experimental studies on rheumatoid arthritis animals. this study with 30 research samples divided into two groups, containing 15 samples each for the treatment group and 15 for the control group. the treatment group was given moringa oleifera extract of 40.50 mg/kgbw/day, while the control group was given a placebo for 30 days.

Eligibility criteria:
inclusion criteria: * diagnosis of ra criteria according to the acr / eular 2010 * visual analog score of more than three. exclusion criteria: * pregnancy * using methylprednisolone\> 8 mg per day * using nsaids * chronic kidney disease * diabetes mellitus * heart failure * lever disease
a study to test whether spesolimab helps people with crohn's disease who have symptoms of bowel obstruction

Conditions: Fibrostenotic Crohn´s Disease

Summary: this study is open to adults, between 18 and 75 years of age, who have narrowings in the small bowel (strictures) due to crohn's disease. strictures can lead to bowel obstruction (blockage). people whose symptoms got worse because of strictures can join the study. participants get standard treatment for crohn's disease and the strictures. the purpose of the study is to test whether the strictures improve further when treated with a medicine called spesolimab added to standard treatment. participants are in the study for about 1 year and 4 months. in the first 3 months, participants get standard treatment only. after 3 months, participants whose condition improved are put into 2 groups randomly, which means by chance. one group gets spesolimab added to their standard treatment. the other group gets placebo added to their standard treatment. both spesolimab and placebo are given as infusions into a vein. placebo infusions look like spesolimab infusions but do not contain any medicine. for the first 2 months, participants get the infusions every month. thereafter, participants get the infusions every 2 months. during the study, participants have about 11 visits to the study site. the doctors regularly check participants' health and take note of any unwanted effects. at 3 of the visits, doctors take images of the bowel using magnetic resonance imaging and with an endoscope. at these visits, the doctors also take a small sample of bowel tissue (biopsy). the participants note their symptoms of crohn's disease and how the symptoms affect daily life in an electronic diary. at the end of the study, results from the diaries and bowel imaging are compared between the spesolimab group and the placebo group.


Eligibility criteria:
inclusion criteria: * 18 to 75 years of legal age * established diagnosis of clinical crohn's disease * suspicion of symptomatic small bowel obstruction at screening * 1 or 2 naïve or anastomotic stenoses in the terminal ileum, with at least one being in reach of ileocolonoscopy as defined by the crohn´s disease antifibrotic stricture therapies (constrict) criteria, confirmed by mre * have achieved a symptomatic stenosis response after optimized anti-inflammatory therapy * absent, mild or moderate endoscopic activity defined by simple endoscopic score in crohn's disease (ses-cd) ≤12 further criteria apply exclusion criteria: * more than 2 small intestinal stenoses * no stenosis is in reach of ileocolonoscopy * patients who require immediate endoscopic balloon dilation or surgical intervention as per the investigator´s discretion or who have undergone any of the two within the 6 months prior to the study * failure of \>2 different biological drug classes * current complications of crohn's disease such as enterocutaneous, internal or rectovaginal fistules, short gut syndrome or abscess, * use of any prohibited concomitant medications as described in the study protocol * active tuberculosis (tb) or history of latent tb that has not been treated further criteria apply
connective tissue disease-associated interstitial lung diseases (ctd-ild) epidemiology non-interventional study (nis)

Conditions: Lung Diseases, Interstitial

Summary: this study aims to characterize the epidemiology of interstitial lung diseases (ild) associated to connective tissue disease (ctd) in mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ild associated to ctd.


Eligibility criteria:
inclusion criteria: for newly data collection: * male and female patients. * patients over 18 years old. * patient who gives his/her signed informed consent to be able to use information about their condition. * patient who has the diagnosis of: rheumatoid arthritis, connective tissue disease (ctd) (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) spondyloarthritis (spa) or sarcoidosis, (accordingly with the updated clinical criteria for each pathology). patient with any interstitial lung diseases (ild) diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist). for existing data collection: * medical records from patients with whom contact was permanently lost for any reason since 2012 till the study start date. * medical records from male and female patients. * medical records from patients over 18 years old. * medical records of patients that have at least: patient initials, date of birth, gender, date of diagnosis, full diagnosis of: * patient who has the diagnosis of: rheumatoid arthritis, ctd (systemic sclerosis or scleroderma; inflammatory myopathy: antisynthetase, dermatomyositis, polymyositis, mixed connective tissue disease; systemic lupus erythematosus; primary sjögren syndrome; pulmonary fibrosis associated with non-specific autoimmunity; primary systemic vasculitis; psoriasis, anchylosing spondylitis, reactive arthritis) spa or sarcoidosis, (accordingly with the updated clinical criteria for each pathology). * patient with any ild diagnosed clinically and by a high-resolution computed tomography study with an interstitial pattern (supervised by an expert radiologist). exclusion criteria: * patient with a biopsy definition of usual interstitial pneumonitis, related to any other non-ctd. * patient with post-chemotherapy or post-radiotherapy pneumonitis. * medical records of patients without full diagnostic of ild (clinically and by biopsy or high-resolution computed tomography).
ultrasound neuromodulation of the brain for alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: this study aims to examine the effects of low-intensity focused ultrasound (lifu) on brain activity in patients with alcohol use disorder.

this is a single-center, double-blind, controlled, randomized, complete block, 2-period crossover pilot trial. the study will assess target engagement of the ventral striatum after lifu in patients with alcohol use disorder using resting state and task-based functional magnetic resonance imaging (fmri).

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 years of age. 2. documentation of an aud diagnosis per dsm-5 criteria as evidenced by problematic pattern of alcohol use leading to clinically significant impairment or distress, as manifested by at least two of the dsm-5 criteria, occurring within a 12-month period. 3. be willing to undergo a brain mri and follow study protocol. exclusion criteria: 1. pregnant or breastfeeding. 2. presence of a condition or abnormality that would compromise the safety of the patient or the quality of the data. 3. non-english speaking. 4. other investigational aud treatments. 5. primary psychosis, bipolar i, or severe personality disorder. 6. active suicidality or history of suicide attempt in the past 5 years. 7. cognitive impairment (moca \<24) 8. significant medical or neurological disease, or life expectancy \<12 mos. 9. significant brain abnormality on brain imaging. 10. any mri exclusion criteria.

Keywords: substance abuse disorder alcohol
evaluation of a cohort of congenital deep deafness patients and/or with auditory neuropathy, looking for dfnb9

Conditions: Congenital Profound Hearing Loss

Summary: evaluation of a cohort of deaf children looking for autosomal recessive deafness-9 (dfnb9). clinical and audiologic evaluation of patients with known auditive neuropathy / auditory dys-synchrony (anad) or recently diagnosed congenital severe to profound hearing loss (hl), and assessing genetic analysis looking for dfnb9. the investigators expect to compile genotypic and phenotypic characterization of 25 children with dfnb9 within 4 years.

anad is not a rare type of hearing loss. nevertheless, its profile is heterogeneous and the pathology remain underdiagnosed. the investigators will screen all new patients with bilateral severe to profound hl, looking for dfnb9. they will analyse their electrophysiology (auditory potential, and otoacoustic emission), and their audio-vestibular profile, at an early stage and one year after inclusion. all patients will be seen in the genetic clinic. also, the investigators will analyse all patients with anad profile and patients known with anad. all informations will provide precise data base to allow a better understanding of the pathology. it might also lead to select the best candidates for future gene therapy

Eligibility criteria:
g1a / inclusion criteria: * child from 0 to 3 years old * child with severe to profound bilateral deafness newly diagnosed with: * average hearing threshold\> 70 decibel on each ear * and / or no response to 70 decibel pea on each ear * and / or no response to assr g1b / inclusion criteria: * child under 16 * child with newly diagnosed hearing neuropathy : tonal/vocal dissociation (when this is possible), and/or modified pea, and/or discordant assr, and/or oea present. g2 / inclusion criteria: * adult patient under 25 or child * patient with deafness with auditory neuropathy * patient known to have 1 or 2 mutations of the otoferlin protein exclusion criteria: * other type of deafness such as : unilateral deafness, deafness of transmission, malformation syndrome, known genetic familial deafness not dfnb9 * patient without medical insurance * lack of consent to dna sampling, of one or both biological parents (consent of the care)

Keywords: auditory neuropathy dfnb9 children hearing loss deafness
effectiveness of automated locomotor training in patients with acute incomplete spinal cord injury: a multicenter trial

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to determine whether longer locomotor training results in a mor favorable outcome in patients with incomplete spinal cord injury.

about half of patients who experience a traumatic spinal cord injury (sci) have still motor and/or sensory function below the level of the lesion. a large proportion of these patients become ambulatory within the first six months after the sci. in order to optimally train the walking function patients are partially unloaded from their body weight while they walk on a moving treadmill. in severe cases therapists have to assist the leg movements which is an exhaustive work limiting training time. in the last few years robotic devices have been developed which enable longer training time. studies evaluating the training of patients with hemiparesis showed that longer training time is associated with a better outcome. the present study aims at evaluating the effect of training time within the robotic device on the recovery of ambulatory function. subject with an acute incomplete sci will be included. the intervention consist of a walking training which lasts at least 50min, the training of the control group last at maximum 25min. both groups will undergo 3-5 trainings per week. group assignment will be performed at random. the study lasts for 8 weeks. the primary outcome will be the self selected walking speed which will be assessed bi-weekly during the training period and 4 months later.

Eligibility criteria:
inclusion criteria: * patients with spinal cord injury (sci) categorized according to the standard classification of the american spinal injury association as asia b or c within the first two weeks after trauma * traumatic etiology of sci * limited walking ability (walking index for spinal cord injury ≤5) * able to start training or rehab within 60 days after trauma * motor level between cervical 4 and thoracic 12 * signed informed consent exclusion criteria: * exclusion criteria of the lokomat:(bodyweight \> 130kg, body height \> 200cm, leg length diff \> 2cm, osteoporosis, instable fracture of lower extremity, restricted range of motion, decubitus ulcer of lower extremity) * concomitant injury limiting walking ability (e.g. lower extremity fractures, instable spine fractures, joint instability preventing weight-bearing, severe soft tissue lesion) * pre-existing medical conditions interfering with unrestricted walking (e.g. total joint replacement, pain, osteoarthritis, polyneuropathy, cardiopulmonary disease) * age older than 65 years or younger than 18 years * conus medullaris or cauda equina syndrome * traumatic brain injury * passive range of motion of the hips, knees and ankles not sufficient to allow normal kinematics consistent with upright gait * patient participates in other rehabilitation or pharmacological study

Keywords: spinal cord injuries, locomotor training, dose-response
comparison of desloratadine associated with prednisolone (tablet)versus dexchlorpheniramine associated with betamethasone (tablet) for adult persistent allergic rhinitis treatment

Conditions: Allergic Rhinitis

Summary: the purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of moderate - severe persistent allergic rhinitis in adults.


Eligibility criteria:
inclusion criteria: * signed consent of the patient; * clinical diagnosis of moderate - severe persistent allergic rhinitis according to aria classification(allergic rhinitis and its impact on asthma); * adults aged ≥ 18 years old; * evidence of sensitization to aeroallergens in examination (immediate skin tests or serum specific ige) in the 12 months prior to inclusion. exclusion criteria: * decongestants dependent patients or patients receiving allergen specific immunotherapy; * patients who were in use of oral antihistamines or decongestants in the past 15 days; * patients who were treated with systemic corticosteroids in the last month; * patients on treatment with monoamine oxidase inhibitors (maois); * patients with history of hypersensitivity to any of the formula compounds; * patients with any clinically significant disease that in the investigator opinion can not participate in the study * patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and nasal anatomic abnormalities. * participation in clinical trial in 30 days prior to study entry;
resting energy expenditure in palliative cancer patients

Conditions: Cancer; Cachexia

Summary: the study purpose is to measure ree by indirect calorimetry and to determine limits of agreement with confidence intervals between measured ree and predictive equations for determination of energy requirements in patients with incurable cancer. clinical factors associated with hyper- and hypometabolism will be elucidated. data will be obtained from patient journals in combination with measurements of ree and registration of survival. data will be collected at one timepoint and survival will be monitored prospectively.


Eligibility criteria:
inclusion criteria: * a verified diagnosis of an incurable malignant disease * hospitalized at the cancer clinic, st. olavs hospital * ≥ 18 years of age * able to provide written informed consent * able to comply with all study procedures exclusion criteria: * cognitive impairment * in need of supplementary oxygen * receiving invasive or noninvasive ventilation